Glucagon-like peptide analogues for type 2 diabetes mellitus.

ABSTRACT:

Background

Glucagon-like peptide analogues are a new class of drugs used in the treatment of type 2 diabetes that mimic the endogenous hormone glucagon-like peptide 1 (GLP-1). GLP-1 is an incretin, a gastrointestinal hormone that is released into the circulation in response to ingested nutrients. GLP-1 regulates glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis, and by suppressing glucagon secretion, delayed gastric emptying and promoting satiety.

Objectives

To assess the effects of glucagon-like peptide analogues in patients with type 2 diabetes mellitus.

Search strategy

Studies were obtained from electronic searches of The Cochrane Library (last search issue 1, 2011), MEDLINE (last search March 2011), EMBASE (last search March 2011),

SUBMITTER: Shyangdan DS 

PROVIDER: S-EPMC6486297 | biostudies-literature | 2011 Oct

REPOSITORIES: biostudies-literature